Project Grant R01DA059182

Award Date 7/1/24
Completion Date 4/30/29
Dollars Obligated $2.1M
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) totaling $945,397 provides funding to the Magee-Womens Research Institute and Foundation, with a sub-award to the University of Pittsburgh, to adapt and evaluate a collaborative care model (CCM) for treating pregnant persons with opioid use disorder (OUD) in low-resource obstetric settings. The key objectives are to: 1) adapt the CCM for rural and low-resource...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $196,236 to The Washington University to conduct research focused on disparities in the prescription and effectiveness of medications to treat opioid use disorder (OUD) during pregnancy. The key objectives of the 5-year project are to: 1) evaluate how race and racial segregation are associated with the use of buprenorphine and methadone as well...
This National Institute on Drug Abuse (NIDA) Project Grant award under CFDA 93.279 (Drug Use and Addiction Research Programs) provides $390,635 to the University of Pittsburgh to develop a novel intervention that addresses prenatal depressive symptoms to encourage tobacco and cannabis cessation among marginalized pregnant and postpartum people. The key products and services to be delivered through this grant include: 1) Conducting formative research on the experiences of marginalized pregnant...
This federal Project Grant award for $1,499,606 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to characterize health outcomes and disparities in children born to individuals with opioid use disorder (OUD). The key products and services to be delivered through this 5-year grant include: Examining variation in the diagnosis of neonatal opioid withdrawal syndrome (NOWS) across 150 hospitals and identifying...
The National Institutes of Health (NIH) awarded Boston Medical Center Corporation a $2,573,346 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The 3-year grant, which commenced on September 1, 2023, will fund a prospective cohort study comparing 100 opioid-exposed pregnancies to 50 non-exposed controls. The study aims to: Compare serial microRNA (miRNA) signatures in opioid-exposed and control pregnancies using maternal plasma and placental tissue samples. The...
The National Institute on Drug Abuse (NIDA) awarded Magee-Womens Research Institute and Foundation a $3,092,159 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to conduct a multimodal analysis of gestational health and placental injury in opioid-affected pregnancies. The goal is to investigate the direct impact of illicit and prescription opioids on placental development, differentiation, and function, focusing on the critical syncytiotrophoblast and...
This Project Grant award, provided by the Substance Abuse and Mental Health Services Administration (SAMHSA) under the Substance Abuse and Mental Health Services Projects of Regional and National Significance (CFDA 93.243) program, will expand the Indiana Pregnancy Promise Program (PROMISE) to serve an additional 300 pregnant individuals with substance use disorder in targeted Indiana counties over the next 3 years. The $894,841 award, effective September 30, 2024, will allow the Indiana...
The National Institute on Drug Abuse (NIDA) awarded The Washington University a 3-year, $2,337,729 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to study the impact of prenatal opioid exposure on placental and fetal brain development. The project, titled "The Opioid in Pregnancy: Imaging of Oxygenation, Inflammation, and Development in Brain & Placenta" (OPIOID BPP), aims to define the longitudinal effects of prenatal opioid exposure on...
This Project Grant award, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will support the development and pilot testing of a peer-based breastfeeding support intervention for mothers with opioid use disorder (OUD). The project aims to: 1) engage mothers with OUD to identify breastfeeding facilitators and understand the potential influence of breastfeeding on recovery; 2) facilitate focus groups with providers, staff, and...
This $6,439,263 federal Project Grant awarded by the National Institute on Drug Abuse (CFDA 93.279 Drug Abuse and Addiction Research Programs) aims to determine the impact of maternal substance use on maternal immune activation, placental function, and offspring neurobehavioral development. The project will leverage the Healthy Brain and Child Development (HBCD) study to perform maternal immune profiling, placental and cord blood analysis, and novel neuroinflammation imaging on 400 pregnancies...

SUBSTANCE USE IN PREGNANCY AND THE MORBIDITY MORTALITY RISK ENVIRONMENT (PROMISE) - ABSTRACT: PEOPLE WHO USE DRUGS (PWUD) AND ARE PREGNANT OR POSTPARTUM ARE TRYING TO SURVIVE AT THE INTERSECTION OF 2 OF THE GRAVEST PUBLIC HEALTH CRISES CONFRONTING THE 21ST CENTURY US: EPIDEMICS OF (1) DRUG-RELATED HARMS, AND (2) MATERNAL MORBIDITY AND MORTALITY. THE US HAS THE HIGHEST RATE OF MATERNAL MORTALITY OF ALL HIGH-INCOME COUNTRIES, AND ANALYSES OF DEATH CERTIFICATES SUGGEST THAT 11% OF DEATHS DURING PREGNANCY AND17% OF POSTPARTUM DEATHS ARE DRUG-RELATED. THIS CRISIS IS ESCALATING: RATES OF OPIOID USE DISORDER DIAGNOSIS AT DELIVERY QUINTUPLED BETWEEN 2004-2015, AND RATES OF AMPHETAMINE-RELATED DIAGNOSIS AT DELIVERY DOUBLED. IN THE MIDST OF THIS ESCALATING CRISIS, PUBLIC HEALTH HAS FAILED TO ADEQUATELY MOBILIZE. INTERVENTION DEVELOP- MENT IS STYMIED BY LIMITED EVIDENCE ABOUT WHICH HARMS PWUD SUFFER WHILE PREGNANT OR POSTPARTUM. TAILORING AND LOCATING INTERVENTIONS IS CHALLENGING, BECAUSE WE KNOW EXCEPTIONALLY LITTLE ABOUT WHO SUFFERS THESE HARMS, OVERALL OR AMONG STRUCTURALLY MARGINALIZED SUBPOPULATIONS; ABOUT WHERE PWUD SUFFERING THESE HARMS CLUSTER SPATIALLY; OR ABOUT WHEN DURING THE HIGHLY DYNAMIC 21 MONTHS OF PREGNANCY AND THE POSTPARTUM YEAR THEY SUF- FER THEM. FURTHER, FEW STUDIES HAVE IDENTIFIED INTERVENTION TARGETS: THE DECADES OF "RISK ENVIRONMENT" RESEARCH ABOUT WHY PWUD IN THE GENERAL (I.E., NOT PREGNANT OR POSTPARTUM) POPULATION EXPERIENCE SPECIFIC DRUG-RELATED HARMS HAS RARELY FOCUSED ON PREGNANT/ POSTPARTUM PEOPLE. BY GENERATING ESSENTIAL EVIDENCE THAT ANSWERS THESE FUNDAMENTAL QUESTIONS, THE PROPOSED LONGITUDINAL STUDY IS DESIGNED TO SUPPORT A NEW ARENA OF INTERVENTIONS TO HELP PWUD SURVIVE THE 21 MONTHS THEY ARE PREGNANT AND POSTPARTUM. BY USING RIGOROUS METHODS TO ANALYZE A NOVEL LONGITUDINAL HOSPITAL DATABASE SPANNING 17 STATES FROM 2017-2022 AND A RECENTLY CREATED CDC MATERNAL MORTALITY DATABASE SPANNING 36 STATES IN 2018-2022, WE WILL GENERATE PANORAMIC EVI- DENCE ABOUT (1A) THE INCIDENCES OF HOSPITAL ENCOUNTERS FOR SPECIFIC DRUG-RELATED MORBIDITIES ACROSS THE 7 QUAR- TERS PWUD ARE PREGNANT AND POSTPARTUM, OVERALL AND BY RACE/ ETHNICITY, INSURANCE STATUS, AND RURALITY, AND (1B) SPATIOTEMPORAL VARIATIONS IN THESE INCIDENCES; AND ABOUT (2A) THE INCIDENCES OF DRUG-RELATED MATERNAL MORTALITY, OVERALL AND BY RACE/ETHNICITY, INSURANCE STATUS, AND RURALITY; AND (2B) SPATIOTEMPORAL VARIATIONS IN THESE INCI- DENCES. GUIDED BY THE INTERSECTIONAL RISK ENVIRONMENT MODEL, WE WILL NEXT (3) APPLY BAYESIAN MODELS TO IDEN- TIFY RISK ENVIRONMENT FEATURES CORRELATED WITH SPATIOTEMPORAL VARIATIONS IN THESE MORBIDITY AND MORTALITY INCI- DENCES, OVERALL AND BY RACE/ETHNICITY, INSURANCE STATUS, AND RURALITY. A NATIONAL ADVISORY BOARD OF PWUD, HARM REDUCTION ADVOCATES, AND REPRODUCTIVE JUSTICE ADVOCATES, AND REPRESENTATIVES OF STATE AGENCIES AND MATERNAL MORTALITY REVIEW COMMITTEES, WILL INFORM THE CONSTRUCTION OF AIM 1 & 2 INCIDENCE MEASURES; PRIORITIZE WHICH RISK ENVIRONMENT FEATURES TO ANALYZE IN AIM 3 & 4; AND SUPPORT DISSEMINATION OF AIM 1-4 RESULTS SO THEY RAPIDLY IN- FORM THE DEVELOPMENT OF INTERVENTIONS TO HELP PWUD SURVIVE THE 21 MONTHS THEY ARE PREGNANT AND POSTPARTUM.

Posted 6/17/24, 12:00 AM